Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 105; no. 23; pp. 8091 - 8096
• Main Authors: Zheng, Bo-Jian, Chan, Kwok-Wah, Lin, Yong-Ping, Zhao, Guang-Yu, Chan, Chris, Zhang, Hao-Jie, Chen, Hong-Lin, Wong, Samson S.Y, Lau, Susanna K.P, Woo, Patrick C.Y, Chan, Kwok-Hung, Jin, Dong-Yan, Yuen, Kwok-Yung
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 10-06-2008; National Acad Sciences
• Subjects: Albumins - metabolism; Animals; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antivirals; Apoptosis; Biological Sciences; Body Weight - drug effects; Chemokines - metabolism; Clinical trials; Cytokines; Female; H5N1 subtype influenza A virus; Immunologic factors; Immunologic Factors - pharmacology; Immunologic Factors - therapeutic use; Infections; Influenza; Influenza A virus; Influenza A Virus, H5N1 Subtype - drug effects; Influenza A Virus, H5N1 Subtype - physiology; Lung - drug effects; Lung - pathology; Lung - virology; Lungs; Lymphocyte Count; Lymphocytes; Mice; Mice, Inbred BALB C; Mortality; Orthomyxoviridae Infections - drug therapy; Prostaglandins - metabolism; Rodents; Survival Analysis; Survival Rate; T-Lymphocytes - drug effects; T-Lymphocytes - virology; Time Factors; Viral Load; Viruses
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.0711942105

The mortality of human infection by influenza A/H5N1 virus can exceed 80%. The high mortality and its poor response to the neuraminidase inhibitor oseltamivir have been attributed to uncontrolled virus-induced cytokine storm. We challenged BALB/c mice with 1,000 LD₅₀ of influenza A/Vietnam/1194/04. Survival, body weight, histopathology, inflammatory markers, viral loads, T lymphocyte counts, and neutralizing antibody response were documented in infected mice treated individually or in combination with zanamvir, celecoxib, gemfibrozil, and mesalazine. To imitate the real-life scenario, treatment was initiated at 48 h after viral challenge. There were significant improvements in survival rate (P = 0.02), survival time (P < 0.02), and inflammatory markers (P < 0.01) in the group treated with a triple combination of zanamivir, celecoxib, and mesalazine when compared with zanamivir alone. Zanamivir with or without immunomodulators reduced viral load to a similar extent. Insignificant prolongation of survival was observed when individual agents were used alone. Significantly higher levels of CD4⁺ and CD8⁺ T lymphocytes and less pulmonary inflammation were also found in the group receiving triple therapy. Zanamivir alone reduced viral load but not inflammation and mortality. The survival benefits of adding celecoxib and mesalazine to zanamivir could be caused by their synergistic effects in reducing cytokine dysfunction and preventing apoptosis. Combinations of a neuraminidase inhibitor with these immunomodulators should be considered in randomized controlled treatment trials of patients suffering from H5N1 infection.